JAK3-IN-20

Overview

JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC 50 of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib ( HY-10227 )-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis . JAK3-IN-20 can be used for the research of Bortezomib -resistant multiple myeloma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > JAK | Products > Signaling Pathways > STAT | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-182314
• CAS No.: 3104109-31-8
• Molecular Formula: C24H31ClN8O2
• Molecular Weight: 499.01
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source